Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/11820
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPryseley, Assam-
dc.contributor.authorTilahun, Abel-
dc.contributor.authorALONSO ABAD, Ariel-
dc.contributor.authorMOLENBERGHS, Geert-
dc.date.accessioned2011-03-18T08:50:39Z-
dc.date.availableNO_RESTRICTION-
dc.date.available2011-03-18T08:50:39Z-
dc.date.issued2011-
dc.identifier.citationLIFETIME DATA ANALYSIS, 17(2). p. 195-214-
dc.identifier.issn1380-7870-
dc.identifier.urihttp://hdl.handle.net/1942/11820-
dc.description.abstractOver the last decades, the evaluation of potential surrogate endpoints in clinical trials has steadily been growing in importance, not only thanks to the availability of ever more potential markers and surrogate endpoints, also because more methodological development has become available. While early work has been devoted, to a large extent, to Gaussian, binary, and longitudinal endpoints, the case of time-to-event endpoints is in need of careful scrutiny as well, owing to the strong presence of such endpoints in oncology and beyond. While work had been done in the past, it was often cumbersome to use such tools in practice, because of the need for fitting copula or frailty models that were further embedded in a hierarchical or two-stage modeling approach. In this paper, we present a methodologically elegant and easy-to-use approach based on information theory. We resolve essential issues, including the quantification of "surrogacy" based on such an approach. Our results are put to the test in a simulation study and are applied to data from clinical trials in oncology. The methodology has been implemented in R.-
dc.description.sponsorshipFinancial support from the IAP research network #P6/03 of the Belgian Government (Belgian Science Policy) is gratefully acknowledged. This work was partially supported by a grant from Coordenadoria para o Aperfeicoamento de Pessoal de Nvel Superior (CAPES), Brazilian science funding agency.-
dc.language.isoen-
dc.publisherSPRINGER-
dc.rights© Springer Science+Business Media, LLC 2010-
dc.subject.otherCancer; Censoring; Information theory; Likelihood reduction factor; Surrogate Marker-
dc.subject.othercancer; censoring; information theory; likelihood reduction factor; surrogate marker-
dc.titleAn information-theoretic approach to surrogate-marker evaluation with failure time endpoints-
dc.typeJournal Contribution-
dc.identifier.epage214-
dc.identifier.issue2-
dc.identifier.spage195-
dc.identifier.volume17-
local.format.pages20-
local.bibliographicCitation.jcatA1-
dc.description.notes[Molenberghs, Geert] Univ Hasselt, B-3590 Diepenbeek, Belgium. [Pryseley, Assam] Singapore Clin Res Inst Pte Ltd, Duke NUS Grad Med Sch, Singapore, Singapore. [Tilahun, Abel] Harvard Univ, Sch Publ Hlth, Dept Biostat, Ctr Biostat AIDS Res, Boston, MA 02115 USA. [Alonso, Ariel] Maastricht Univ, Dept Methodol & Stat, NL-6200 MD Maastricht, Netherlands. [Molenberghs, Geert] Katholieke Univ Leuven, B-3000 Louvain, Belgium.-
local.type.refereedRefereed-
local.type.specifiedArticle-
dc.bibliographicCitation.oldjcatA1-
dc.identifier.doi10.1007/s10985-010-9185-6-
dc.identifier.isi000287664500002-
item.fulltextWith Fulltext-
item.contributorPryseley, Assam-
item.contributorTilahun, Abel-
item.contributorALONSO ABAD, Ariel-
item.contributorMOLENBERGHS, Geert-
item.fullcitationPryseley, Assam; Tilahun, Abel; ALONSO ABAD, Ariel & MOLENBERGHS, Geert (2011) An information-theoretic approach to surrogate-marker evaluation with failure time endpoints. In: LIFETIME DATA ANALYSIS, 17(2). p. 195-214.-
item.accessRightsRestricted Access-
item.validationecoom 2012-
crisitem.journal.issn1380-7870-
crisitem.journal.eissn1572-9249-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
a.pdf
  Restricted Access
Published version273.49 kBAdobe PDFView/Open    Request a copy
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.